MedTrace Logo

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect of a single oral dose of TAK-071 on the attenuation of cognitive deficit induced by scopolamine as measured by Groton Maze Learning Test (GMLT) (total number of errors).

Conditions

  • Healthy Volunteers

Interventions

DRUG

Scopolamine

Scopolamine subcutaneous injection

DRUG

TAK-071

TAK-071 DIC

DRUG

Donepezil

Donepezil over-encapsulated tablet

DRUG

Scopolamine Placebo

Scopolamine placebo-matching subcutaneous injection

DRUG

TAK-071 Placebo

TAK-071 placebo-matching DIC

DRUG

Donepezil Placebo

Donepezil placebo-matching over-encapsulated tablet

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-21
Primary Completion
2017-08-02
Completion
2017-08-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02918266 on ClinicalTrials.gov